Summary by Moomoo AI
Cardio Diagnostics Holdings, Inc., a company specializing in health diagnostics, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on January 26, 2024, will not undergo review by the agency. The SEC's communication, dated January 30, 2024, was addressed to Dr. Meeshanthini Dogan, the Chief Executive Officer of Cardio Diagnostics Holdings. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. Daniel Crawford from the Division of Corporation Finance Office of Life Sciences is the contact person for any further inquiries.